Top-Rated StocksTop-RatedNASDAQ:KRTX Karuna Therapeutics (KRTX) Stock Forecast, Price & News $236.30 +2.02 (+0.86%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$233.60▼$238.4850-Day Range$176.32▼$236.3052-Week Range$93.47▼$278.25Volume432,971 shsAverage Volume285,887 shsMarket Capitalization$8.85 billionP/E RatioN/ADividend YieldN/APrice Target$277.13 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Karuna Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside16.6% Upside$275.44 Price TargetShort InterestBearish5.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 9 Articles This WeekInsider TradingSelling Shares$13.03 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($11.67) to ($11.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.62 out of 5 starsMedical Sector829th out of 982 stocksPharmaceutical Preparations Industry408th out of 476 stocks 2.4 Analyst's Opinion Consensus RatingKaruna Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $275.44, Karuna Therapeutics has a forecasted upside of 16.6% from its current price of $236.30.Amount of Analyst CoverageKaruna Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.56% of the outstanding shares of Karuna Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaruna Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Karuna Therapeutics has recently decreased by 2.35%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKaruna Therapeutics does not currently pay a dividend.Dividend GrowthKaruna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRTX. Previous Next 2.4 News and Social Media Coverage News SentimentKaruna Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Karuna Therapeutics this week, compared to 4 articles on an average week.MarketBeat Follows5 people have added Karuna Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karuna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,030,410.00 in company stock.Percentage Held by Insiders16.20% of the stock of Karuna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karuna Therapeutics are expected to grow in the coming year, from ($11.67) to ($11.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karuna Therapeutics is -24.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karuna Therapeutics is -24.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKaruna Therapeutics has a P/B Ratio of 7.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Karuna Therapeutics (NASDAQ:KRTX) StockKaruna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.Read More Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KRTX Stock News HeadlinesJune 6, 2023 | seekingalpha.comKaruna Therapeutics: Great Company, But Not A Great Buy Right NowJune 5, 2023 | msn.comJP Morgan Maintains Karuna Therapeutics (KRTX) Overweight RecommendationJune 7, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.June 5, 2023 | americanbankingnews.comKaruna Therapeutics (NASDAQ:KRTX) Price Target Lowered to $250.00 at JPMorgan Chase & Co.June 1, 2023 | nasdaq.comJMP Securities Reiterates Karuna Therapeutics (KRTX) Market Outperform RecommendationJune 1, 2023 | markets.businessinsider.comCiti Keeps Their Buy Rating on Karuna Therapeutics (KRTX)May 31, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Karuna Therapeutics (KRTX)May 30, 2023 | finance.yahoo.comKaruna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceJune 7, 2023 | Edge On The Street (Ad)Nevada Desert more Valuable than Wall Street or Silicon Valley?It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.May 28, 2023 | americanbankingnews.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) CFO Sells $2,010,690.00 in StockMay 26, 2023 | finance.yahoo.comInvesting in Karuna Therapeutics (NASDAQ:KRTX) three years ago would have delivered you a 144% gainMay 22, 2023 | finance.yahoo.comKaruna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual MeetingMay 21, 2023 | markets.businessinsider.comMizuho Securities Sticks to Its Buy Rating for Karuna Therapeutics (KRTX)May 20, 2023 | americanbankingnews.comAnalysts Set Karuna Therapeutics, Inc. (NASDAQ:KRTX) PT at $277.13May 18, 2023 | americanbankingnews.comKaruna Therapeutics (NASDAQ:KRTX) Stock Price Down 5.6%May 16, 2023 | msn.comHC Wainwright & Co. Reiterates Karuna Therapeutics (KRTX) Buy RecommendationMay 12, 2023 | msn.comKaruna Therapeutics's Return On Capital Employed OverviewMay 12, 2023 | americanbankingnews.comEquities Analysts Offer Predictions for Karuna Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:KRTX)May 9, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Karuna Therapeutics (KRTX)May 9, 2023 | americanbankingnews.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Forecasted to Earn Q2 2024 Earnings of ($3.47) Per ShareMay 8, 2023 | msn.comMizuho Maintains Karuna Therapeutics (KRTX) Buy RecommendationMay 8, 2023 | msn.comOppenheimer Reiterates Karuna Therapeutics (KRTX) Outperform RecommendationMay 8, 2023 | americanbankingnews.comKaruna Therapeutics (NASDAQ:KRTX) PT Raised to $274.00 at MizuhoMay 6, 2023 | msn.comCitigroup Maintains Karuna Therapeutics (KRTX) Buy RecommendationMay 6, 2023 | msn.comRBC Capital Maintains Karuna Therapeutics (KRTX) Outperform RecommendationMay 5, 2023 | markets.businessinsider.comBerenberg Bank Remains a Buy on Karuna Therapeutics (KRTX)May 5, 2023 | finance.yahoo.comKaruna (KRTX) Reports Narrower-Than-Expected Loss in Q1See More Headlines KRTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRTX Company Calendar Last Earnings5/04/2023Today6/06/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRTX CUSIPN/A CIK1771917 Webkarunatx.com Phone(857) 449-2244FaxN/AEmployees118Year FoundedN/APrice Target and Rating Average Stock Price Forecast$275.44 High Stock Price Forecast$330.00 Low Stock Price Forecast$209.00 Forecasted Upside/Downside+17.3%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($9.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,340,000.00 Net Margins-2,795.96% Pretax Margin-2,783.40% Return on Equity-30.04% Return on Assets-29.09% Debt Debt-to-Equity RatioN/A Current Ratio59.74 Quick Ratio59.74 Sales & Book Value Annual Sales$10.64 million Price / Sales831.49 Cash FlowN/A Price / Cash FlowN/A Book Value$32.78 per share Price / Book7.21Miscellaneous Outstanding Shares37,440,000Free Float31,378,000Market Cap$8.85 billion OptionableNot Optionable Beta1.15 Key ExecutivesWilliam J. MeuryPresident, Chief Executive Officer & DirectorAndrew MillerChief Operating OfficerTroy A. IgnelziChief Financial OfficerStephen BrannanChief Medical OfficerSteven Marc PaulDirector, Chief Scientific Officer, President-R&DKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZTeva Pharmaceutical IndustriesNYSE:TEVADr. Reddy's LaboratoriesNYSE:RDYPrometheus BiosciencesNASDAQ:RXDXUnited TherapeuticsNASDAQ:UTHRView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 1,726 shares on 6/1/2023Ownership: 0.005%ProShare Advisors LLCSold 519 shares on 5/26/2023Ownership: 0.017%Troy A IgnelziSold 9,000 sharesTotal: $2.01 M ($223.41/share)Capital Impact Advisors LLCBought 2,143 shares on 5/23/2023Ownership: 0.006%Putnam Investments LLCSold 515 shares on 5/22/2023Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions KRTX Stock - Frequently Asked Questions Should I buy or sell Karuna Therapeutics stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRTX shares. View KRTX analyst ratings or view top-rated stocks. What is Karuna Therapeutics' stock price forecast for 2023? 15 Wall Street analysts have issued 1-year target prices for Karuna Therapeutics' stock. Their KRTX share price forecasts range from $209.00 to $330.00. On average, they predict the company's stock price to reach $275.44 in the next year. This suggests a possible upside of 16.6% from the stock's current price. View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts. How have KRTX shares performed in 2023? Karuna Therapeutics' stock was trading at $196.50 on January 1st, 2023. Since then, KRTX stock has increased by 20.3% and is now trading at $236.30. View the best growth stocks for 2023 here. When is Karuna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our KRTX earnings forecast. How were Karuna Therapeutics' earnings last quarter? Karuna Therapeutics, Inc. (NASDAQ:KRTX) posted its earnings results on Thursday, May, 4th. The company reported ($2.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.86) by $0.06. The business earned $0.65 million during the quarter. Karuna Therapeutics had a negative trailing twelve-month return on equity of 30.04% and a negative net margin of 2,795.96%. During the same period in the previous year, the company posted ($1.95) earnings per share. What ETFs hold Karuna Therapeutics' stock? ETFs with the largest weight of Karuna Therapeutics (NASDAQ:KRTX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Nuveen ESG Small-Cap ETF (NUSC) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Karuna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS). When did Karuna Therapeutics IPO? (KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Karuna Therapeutics' stock symbol? Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX." Who are Karuna Therapeutics' major shareholders? Karuna Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.97%), Price T Rowe Associates Inc. MD (6.63%), BlackRock Inc. (6.60%), Wellington Management Group LLP (4.29%), State Street Corp (2.66%) and Geode Capital Management LLC (1.61%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi. View institutional ownership trends. How do I buy shares of Karuna Therapeutics? Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Karuna Therapeutics' stock price today? One share of KRTX stock can currently be purchased for approximately $236.30. How much money does Karuna Therapeutics make? Karuna Therapeutics (NASDAQ:KRTX) has a market capitalization of $8.85 billion and generates $10.64 million in revenue each year. The company earns $-276,340,000.00 in net income (profit) each year or ($9.57) on an earnings per share basis. How many employees does Karuna Therapeutics have? The company employs 118 workers across the globe. How can I contact Karuna Therapeutics? Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The official website for the company is karunatx.com. The company can be reached via phone at (857) 449-2244 or via email at investors@karunatx.com. This page (NASDAQ:KRTX) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.